Wyeth Extends and Expands Its Licensing of Ingenuity Pathways Analysis
News Oct 27, 2005
Ingenuity has announced that Wyeth Pharmaceuticals, Inc. has extended and expanded it’s licensing of the Ingenuity Pathways Analysis software and will be deploying it broadly across its discovery and development organizations worldwide.
Ingenuity Pathways Analysis (IPA) 3.0, released last month, designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
With Ingenuity Pathways Analysis 3.0, scientists can integrate their own biological discoveries into Ingenuity networks, enabling computation and functional analysis.
IPA 3.0 allows scientists to create customized pathways for particular targets, biomarkers, disease areas, and processes, leveraging Ingenuity's broad knowledge base of biological relationships between genes and proteins, cells, tissues, and diseases.
“Wyeth continues to embrace pathways analysis software as a critical element to successful therapeutic research and development,” stated Peter DiLaura, Vice President, Sales and Customer Support.
“Ingenuity is pleased that Wyeth is both renewing and expanding its use of Ingenuity technology, and Ingenuity will continue its commitment to provide the highest quality pathways solutions available today.”
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available to qualified scientists.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.